BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8129746)

  • 1. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines.
    Johnson SW; Perez RP; Godwin AK; Yeung AT; Handel LM; Ozols RF; Hamilton TC
    Biochem Pharmacol; 1994 Feb; 47(4):689-97. PubMed ID: 8129746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
    Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
    Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
    Shellard SA; Hosking LK; Hill BT
    Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.
    Zhen W; Link CJ; O'Connor PM; Reed E; Parker R; Howell SB; Bohr VA
    Mol Cell Biol; 1992 Sep; 12(9):3689-98. PubMed ID: 1380646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines.
    Johnson SW; Shen D; Pastan I; Gottesman MM; Hamilton TC
    Exp Cell Res; 1996 Jul; 226(1):133-9. PubMed ID: 8660948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
    McKeage MJ; Abel G; Kelland LR; Harrap KR
    Br J Cancer; 1994 Jan; 69(1):1-7. PubMed ID: 8286188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.
    Materna V; Liedert B; Thomale J; Lage H
    Int J Cancer; 2005 Jun; 115(3):393-402. PubMed ID: 15688364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation.
    Hill BT; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Bedford P
    Int J Radiat Oncol Biol Phys; 1990 Jul; 19(1):75-83. PubMed ID: 2380098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ; Kelland LR
    Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.
    Parker RJ; Vionnet JA; Bostick-Bruton F; Reed E
    Cancer Res; 1993 Jan; 53(2):242-7. PubMed ID: 8417816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
    Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
    Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line.
    Shellard SA; Hosking LK; Hill BT
    Biochem Pharmacol; 1994 Mar; 47(5):775-9. PubMed ID: 8135853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
    Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.
    Liedert B; Materna V; Schadendorf D; Thomale J; Lage H
    J Invest Dermatol; 2003 Jul; 121(1):172-6. PubMed ID: 12839578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro.
    Dempke WC; Shellard SA; Fichtinger-Schepman AM; Hill BT
    Carcinogenesis; 1991 Mar; 12(3):525-8. PubMed ID: 1901253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
    Johnson SW; Laub PB; Beesley JS; Ozols RF; Hamilton TC
    Cancer Res; 1997 Mar; 57(5):850-6. PubMed ID: 9041185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
    Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
    Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.
    Deqnah N; Yu JQ; Beale P; Fisher K; Huq F
    Anticancer Res; 2012 Jan; 32(1):135-40. PubMed ID: 22213298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.